| 摘要 |
A polypeptide consists of a variable region of the light or heavy chains of an antibody of a species selectively binding the human mammary fat globule (HMFG) antigen, and an antigen found on the surface or the cytoplasm of tumor cells such as carcinoma cells or that is released by the cells, combinations thereof operatively linked to one another, and mixtures thereof. The polypeptide may be glycosylated. A hybrid polypeptide comprises the polypeptide of the invention and an effector agent, and both polypeptides may be present as a composition with a non-proteolytic carrier as well as with a pharmaceutically acceptable carrier. Diagnostic kits comprises the polypeptide or hybrid polypeptide of the invention and other components such as anti-tumor antibody, and anti-constant region immunoglobulin, protein G or A, a solid support, and instructions for their use. Tumors may be imaged and/or diagnosed in vivo by administering the radiolabeled polypeptide of this invention and detecting any localized labeled polypeptide, and in vitro by contacting a biological sample with the hybrid polypeptide of the invention to form a complex with neoplastic antigen present in the sample, and detecting any complex formed. The growth or the size of a primary or metastasized tumor may be therapeutically inhibited or reduced by administering the polypeptide or hybrid polypeptide of the invention. A polynucleotide comprises an oligonucleotide encoding the polypeptide or hybrid polypeptide described above, hybrid vectors carry the polydeoxyribonucleotide(s) of the invention, and host cells are transfected with the hybrid vectors. Te polypeptide or hybrid polypeptide may be obtained by cloning one or more of the polydeoxyribonucleotide(s) of this invention. An anti-idiotype polypeptide comprises polyclonal antibodies raised against the polypeptide of this invention; monoclonal antibodies thereof; Fab, Fab', (Fab')2, and variable region fragments thereof; an oligopeptide comprising the amino acid sequence APDTRPA or tandem repeats thereof, combinations thereof and mixtures thereof. The hybrid polypeptide may also contain an effector agent and be provided as an anti-neoplastic vaccine in a vaccination kit. The serum concentration of a circulating polypeptide that binds to an antigen present on the surface or in the cytoplasm of tumor cells or that are released by the cells may be lowered by administering the anti-idiotype polypeptide of the invention to accelerate the clearance of the polypeptide. |
